Figures & data
Figure 1 Chronology of clinical trials 1 and 2, indicating assessment of pain thresholds (*), elapsed times, drug administration, and blood samplings (♦), and blood samplings only for clinical trial 2.
![Figure 1 Chronology of clinical trials 1 and 2, indicating assessment of pain thresholds (*), elapsed times, drug administration, and blood samplings (♦), and blood samplings only for clinical trial 2.](/cms/asset/b8c3199b-3495-4a0a-a47a-bbbeb8fcde2d/dddt_a_63476_f0001_b.jpg)
Table 1 Clinical trial 1: descriptive statistics on pharmacokinetic parameters
Table 2 Clinical trials 1 (CT1) and 2 (CT2): descriptive statistics on pharmacodynamic-derived parameters (pain thresholds)
Figure 3 Antinociceptive profiles obtained during (A) clinical trial 1 for 1 g intravenous (iv) and 250 mg buccal (b) acetaminophen (APAP) and (B) during clinical trial 2 for 1 g iv APAP, 125 mg bAPAP, and 125 mg sublingual (s)APAP.
Abbreviation: PT, pain threshold.
![Figure 3 Antinociceptive profiles obtained during (A) clinical trial 1 for 1 g intravenous (iv) and 250 mg buccal (b) acetaminophen (APAP) and (B) during clinical trial 2 for 1 g iv APAP, 125 mg bAPAP, and 125 mg sublingual (s)APAP.](/cms/asset/0ce5c6de-a01f-4931-90d1-bb9c85cce6c9/dddt_a_63476_f0003_b.jpg)